S&P 500   2,999.70 (+0.33%)
DOW   27,036.31 (+0.13%)
QQQ   193.44 (+0.21%)
AAPL   234.33 (-0.02%)
FB   189.52 (-0.02%)
MSFT   139.63 (-0.56%)
GOOGL   1,255.77 (+1.03%)
AMZN   1,791.30 (+0.78%)
CGC   20.04 (+1.57%)
NVDA   193.98 (-0.12%)
MU   45.48 (+0.71%)
BABA   176.49 (-0.36%)
GE   9.09 (+2.14%)
TSLA   261.81 (+0.79%)
AMD   31.18 (+1.20%)
ACB   3.75 (+3.88%)
BAC   30.33 (+0.53%)
GILD   65.36 (+0.02%)
DIS   133.07 (+1.68%)
S&P 500   2,999.70 (+0.33%)
DOW   27,036.31 (+0.13%)
QQQ   193.44 (+0.21%)
AAPL   234.33 (-0.02%)
FB   189.52 (-0.02%)
MSFT   139.63 (-0.56%)
GOOGL   1,255.77 (+1.03%)
AMZN   1,791.30 (+0.78%)
CGC   20.04 (+1.57%)
NVDA   193.98 (-0.12%)
MU   45.48 (+0.71%)
BABA   176.49 (-0.36%)
GE   9.09 (+2.14%)
TSLA   261.81 (+0.79%)
AMD   31.18 (+1.20%)
ACB   3.75 (+3.88%)
BAC   30.33 (+0.53%)
GILD   65.36 (+0.02%)
DIS   133.07 (+1.68%)
Log in

ResMed Stock Price, News & Analysis (NYSE:RMD)

$131.91
+0.75 (+0.57 %)
(As of 10/17/2019 11:31 AM ET)
Today's Range
$131.20
Now: $131.91
$132.72
50-Day Range
$128.30
MA: $134.23
$141.19
52-Week Range
$90.64
Now: $131.91
$141.25
Volume91,188 shs
Average Volume498,491 shs
Market Capitalization$18.96 billion
P/E Ratio36.24
Dividend Yield1.21%
Beta0.41
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.61 billion
Cash Flow$4.81 per share
Book Value$14.42 per share

Profitability

Net Income$404.59 million

Miscellaneous

Employees7,240
Market Cap$18.96 billion
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.


ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, July 25th. Investors of record on Thursday, August 15th will be given a dividend of $0.39 per share on Thursday, September 19th. This represents a $1.56 annualized dividend and a yield of 1.18%. The ex-dividend date is Wednesday, August 14th. This is an increase from ResMed's previous quarterly dividend of $0.37. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its earnings results on Thursday, July, 25th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.03. The medical equipment provider earned $705 million during the quarter, compared to analyst estimates of $701.56 million. ResMed had a net margin of 15.52% and a return on equity of 26.49%. The business's revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the business earned $0.95 earnings per share. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for ResMed.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for RMD?

6 brokerages have issued twelve-month target prices for ResMed's shares. Their forecasts range from $95.00 to $140.00. On average, they expect ResMed's share price to reach $118.33 in the next twelve months. This suggests that the stock has a possible downside of 10.3%. View Analyst Price Targets for ResMed.

What is the consensus analysts' recommendation for ResMed?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.

Has ResMed been receiving favorable news coverage?

Media headlines about RMD stock have trended very negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ResMed earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for ResMed.

Are investors shorting ResMed?

ResMed saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,910,000 shares, a decrease of 18.0% from the August 30th total of 2,330,000 shares. Based on an average trading volume of 513,800 shares, the short-interest ratio is presently 3.7 days. Currently, 1.3% of the shares of the stock are sold short. View ResMed's Current Options Chain.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include Energy Transfer LP Unit (ET), Starbucks (SBUX), Netflix (NFLX), Walt Disney (DIS), Visa (V), Mastercard (MA), CBL & Associates Properties (CBL), AT&T (T), Intel (INTC) and Ford Motor (F).

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
  • Mr. Robert A. Douglas, Pres & COO (Age 59)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

Who are ResMed's major shareholders?

ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Welch & Forbes LLC (0.21%), Capital Investment Services of America Inc. (0.11%), Gateway Investment Advisers LLC (0.08%), West Coast Financial LLC (0.03%), Security National Bank (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gateway Investment Advisers LLC, Welch & Forbes LLC, Gulf International Bank UK Ltd, Rockland Trust Co., First Hawaiian Bank and Financial Gravity Wealth Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which institutional investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Landsberg Bennett & Dubbaneh LLC, State of Alaska Department of Revenue, Surevest Inc., Campbell Capital Management Inc., Patten & Patten Inc. TN, Park National Corp OH, Starfire Investment Advisers Inc. and Pacer Advisors Inc.. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $131.91.

How big of a company is ResMed?

ResMed has a market capitalization of $18.96 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.

What is ResMed's official website?

The official website for ResMed is http://www.resmed.com/.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]


MarketBeat Community Rating for ResMed (NYSE RMD)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  582 (Vote Underperform)
Total Votes:  896
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel